奥比他韦/帕立普韦/利托那韦联合达沙布韦治疗晚期慢性肾脏病患者丙型肝炎病毒1型和4型的疗效与安全性
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir in Treating HCV Genotypes 1 and 4 in Patients with Advanced Chronic Kidney Disease.
作者信息
Aljarallah Badr M
机构信息
Department of Medicine, Division of Gastroenterology and Hepatology, College of Medicine, Qassim University, Buraydah, Saudi Arabia.
出版信息
J Pharm Bioallied Sci. 2024 Jul;16(Suppl 3):S2224-S2227. doi: 10.4103/jpbs.jpbs_143_24. Epub 2024 Jul 5.
Abstract
This study assessed the efficacy and safety of ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) combined with dasabuvir (DSV) for treating hepatitis C genotype 4 (GT4) and genotype 1 (GT1) in patients with stage 4 or 5 chronic kidney disease (CKD). Among 88 patients, including treatment-naïve and Peginterferon/Ribavirin (RBV)-experienced, treated with OBV/PTV/r±RBV (dosed between 200 mg per week to daily) and additional DSV for GT1, 94.3% achieved sustained virologic response at 12 weeks (SVR12), demonstrating high efficacy. RBV was used at the discretion of the treating physician. The treatment was well-tolerated, with two non-treatment-related deaths reported. The findings suggest that a 12-week regimen of OBV/PTV/r±DSV is highly effective and safe for GT1 and GT4 patients with advanced CKD, regardless of baseline characteristics.
摘要
本研究评估了奥比他韦/帕利哌韦/利托那韦（OBV/PTV/r）联合达沙布韦（DSV）治疗4期或5期慢性肾脏病（CKD）患者丙型肝炎基因4型（GT4）和基因1型（GT1）的疗效和安全性。在88例患者中，包括初治患者和曾接受聚乙二醇干扰素/利巴韦林（RBV）治疗的患者，接受OBV/PTV/r±RBV（剂量为每周200 mg至每日给药）及额外的GT1 DSV治疗，94.3%的患者在12周时实现了持续病毒学应答（SVR12），显示出高疗效。RBV由治疗医生酌情使用。治疗耐受性良好，报告了两例与治疗无关的死亡病例。研究结果表明，无论基线特征如何，为期12周的OBV/PTV/r±DSV方案对晚期CKD的GT1和GT4患者具有高度有效性和安全性。
相似文献
1
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir in Treating HCV Genotypes 1 and 4 in Patients with Advanced Chronic Kidney Disease.奥比他韦/帕立普韦/利托那韦联合达沙布韦治疗晚期慢性肾脏病患者丙型肝炎病毒1型和4型的疗效与安全性
J Pharm Bioallied Sci. 2024 Jul;16(Suppl 3):S2224-S2227. doi: 10.4103/jpbs.jpbs_143_24. Epub 2024 Jul 5.
2
High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.奥比他韦/帕利瑞韦/利托那韦联合达萨布韦治疗合并严重慢性肾脏病的基因 4 型和 1 型丙型肝炎患者的高效性。
Liver Int. 2018 Aug;38(8):1395-1401. doi: 10.1111/liv.13674. Epub 2018 Mar 31.
3
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.奥比他韦/帕利瑞韦/达沙布韦与含干扰素方案相比在治疗 HCV 基因 1 型患者中的疗效和安全性：MALACHITE-I/II 试验。
J Hepatol. 2016 Jan;64(1):19-28. doi: 10.1016/j.jhep.2015.08.015. Epub 2015 Aug 29.
4
Ombitasvir/paritaprevir/ritonavir and dasabuvir±ribavirin for chronic HCV infection in US veterans with psychiatric disorders.奥比他韦/帕利瑞韦/利托那韦和达萨布韦±利巴韦林治疗伴有精神障碍的美国退伍军人慢性 HCV 感染。
J Med Virol. 2020 Dec;92(12):3459-3464. doi: 10.1002/jmv.25655. Epub 2020 Feb 17.
5
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease.奥比他韦/帕利瑞韦/利托那韦治疗丙型肝炎病毒1型或4型感染合并晚期肾病患者的疗效与安全性
Kidney Int Rep. 2018 Oct 9;4(2):257-266. doi: 10.1016/j.ekir.2018.10.003. eCollection 2019 Feb.
6
Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.ombitasvir/paritaprevir/ritonavir联合达沙布韦治疗对重度肾功能不全的1型和4型丙型肝炎病毒（HCV）感染患者有效且安全：一项多中心经验。
J Viral Hepat. 2017 Jun;24(6):464-471. doi: 10.1111/jvh.12664. Epub 2017 Jan 20.
7
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.在患有不同合并症和合并用药的丙型肝炎病毒基因型 1 和 4 感染患者中，奥比他韦/帕利他韦/利托那韦±达萨布韦±利巴韦林的真实世界安全性和有效性：来自 13 个国家的上市后观察性研究的 pooled 分析。
J Viral Hepat. 2019 Jun;26(6):685-696. doi: 10.1111/jvh.13080. Epub 2019 Mar 5.
8
Ombitasvir/Paritaprevir/Ritonavir With or Without Dasabuvir and With or Without Ribavirin for Adolescents With HCV Genotype 1 or 4.奥比他韦/帕利瑞韦/利托那韦联合或不联合达沙布韦以及联合或不联合利巴韦林用于治疗 HCV 基因型 1 或 4 的青少年患者。
Hepatol Commun. 2018 Oct 5;2(11):1311-1319. doi: 10.1002/hep4.1250. eCollection 2018 Nov.
9
Safety and Efficacy of Ombitasvir, Paritaprevir With Ritonavir ± Dasabuvir With or Without Ribavirin in Patients With Human Immunodeficiency Virus-1 and Hepatitis C Virus Genotype 1 or Genotype 4 Coinfection: TURQUOISE-I Part 2.奥比他韦、帕利瑞韦联合利托那韦±达沙布韦加或不加利巴韦林治疗人类免疫缺陷病毒1型和丙型肝炎病毒1型或4型合并感染患者的安全性和有效性：TURQUOISE-I研究第2部分
Open Forum Infect Dis. 2017 Jul 22;4(3):ofx154. doi: 10.1093/ofid/ofx154. eCollection 2017 Summer.
10
Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.奥比他韦/帕立普韦/利托那韦/ +达沙布韦±利巴韦林（OBV/PTV/r/ +DSV±RBV）治疗肝移植后复发性丙型肝炎病毒（HCV）1型感染的真实世界安全性和有效性：AMBER-CEE研究
Ann Transplant. 2017 Apr 7;22:199-207. doi: 10.12659/aot.903535.
引用本文的文献
1
Development of an electrochemical sensor using molecularly imprinted polymers for the specific determination of the antiretroviral drug ritonavir.一种使用分子印迹聚合物的电化学传感器的开发，用于抗逆转录病毒药物利托那韦的特异性测定。
Mikrochim Acta. 2025 Aug 6;192(9):560. doi: 10.1007/s00604-025-07427-z.
本文引用的文献
1
Health Indicators for Renal Replacement Therapy in Saudi Arabia.沙特阿拉伯肾脏替代治疗的健康指标
Transplant Proc. 2019 Mar;51(2):509-511. doi: 10.1016/j.transproceed.2019.01.011. Epub 2019 Jan 4.
2
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir in Patients With Hepatitis C Virus Genotype 1 or 4 Infection and Advanced Kidney Disease.奥比他韦/帕利瑞韦/利托那韦治疗丙型肝炎病毒1型或4型感染合并晚期肾病患者的疗效与安全性
Kidney Int Rep. 2018 Oct 9;4(2):257-266. doi: 10.1016/j.ekir.2018.10.003. eCollection 2019 Feb.
3
Grazoprevir plus elbasvir in HCV genotype-1 or -4 infected patients with stage 4/5 severe chronic kidney disease is safe and effective.格拉瑞韦联合艾尔巴韦格拉瑞韦治疗 4/5 期重度慢性肾脏病合并 HCV 基因型 1 或 4 感染患者是安全有效的。
Kidney Int. 2018 Jul;94(1):206-213. doi: 10.1016/j.kint.2018.02.019. Epub 2018 May 5.
4
Glecaprevir and Pibrentasvir in Patients with HCV and Severe Renal Impairment.格卡瑞韦和哌仑他韦治疗丙型肝炎病毒合并严重肾功能损害患者。
N Engl J Med. 2017 Oct 12;377(15):1448-1455. doi: 10.1056/NEJMoa1704053.
5
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study.2015 年全球丙型肝炎病毒感染的流行率和基因型分布：一项建模研究。
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176. doi: 10.1016/S2468-1253(16)30181-9. Epub 2016 Dec 16.
6
Therapy with ombitasvir/paritaprevir/ritonavir plus dasabuvir is effective and safe for the treatment of genotypes 1 and 4 hepatitis C virus (HCV) infection in patients with severe renal impairment: A multicentre experience.ombitasvir/paritaprevir/ritonavir联合达沙布韦治疗对重度肾功能不全的1型和4型丙型肝炎病毒（HCV）感染患者有效且安全：一项多中心经验。
J Viral Hepat. 2017 Jun;24(6):464-471. doi: 10.1111/jvh.12664. Epub 2017 Jan 20.
7
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.奥贝他韦/帕利瑞韦/利托那韦 ± 达萨布韦 ± 利巴韦林治疗丙型肝炎的真实世界疗效和安全性：AMBER 研究。
Aliment Pharmacol Ther. 2016 Nov;44(9):946-956. doi: 10.1111/apt.13790. Epub 2016 Sep 9.
8
SASLT guidelines: Update in treatment of Hepatitis C virus infection.《SASLT指南：丙型肝炎病毒感染治疗的更新》
Saudi J Gastroenterol. 2016 Aug;22 Suppl(Suppl 2):S25-57. doi: 10.4103/1319-3767.188067.
9
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.直接作用抗病毒药物联合治疗方案对丙型肝炎病毒 1 型感染且伴有严重肾功能损害或终末期肾病患者的疗效。
Gastroenterology. 2016 Jun;150(7):1590-1598. doi: 10.1053/j.gastro.2016.02.078. Epub 2016 Mar 11.
10
Grazoprevir plus elbasvir in treatment-naive and treatment-experienced patients with hepatitis C virus genotype 1 infection and stage 4-5 chronic kidney disease (the C-SURFER study): a combination phase 3 study.格拉瑞韦联合艾尔巴韦在初治和经治的丙型肝炎病毒基因型 1 感染和 4-5 期慢性肾脏病患者中的疗效（C-SURFER 研究）：一项联合 III 期研究。
Lancet. 2015 Oct 17;386(10003):1537-45. doi: 10.1016/S0140-6736(15)00349-9. Epub 2015 Oct 5.
Zotero 插件